In 2784 specimens submitted to the Clinical Microbiology Laboratory of the Instituto Nacional de Neurología from May 1989 to January 1990, 140 (5.0%) had gram negative bacilli (GNB) resistant to five or more antibiotics. One hundred different isolates recovered from urine, tracheal aspirates, blood, cerebrospinal fluid, surgical wound infections and other sites were studied. Pseudomonas spp, Enterobacter spp, Klebsiella pneumoniae and Escherichia coli accounted for 86% of the total. Disk diffusion susceptibility tests with the NCCLS method revealed 59 to 67% of isolates susceptible to amikacin, ciprofloxacin and ceftazidime. Sixteen to 30% were inhibited by piperacillin, cefoperazone and cefotaxime. Less than 10% were susceptible to carbenicillin, tobramycin, gentamicin, cephalothin and ampicillin. Minimum inhibitory concentrations (MIC) to amikacin and ciprofloxacin were determined by broth macrotube dilution in Mueller-Hinton broth supplemented with Ca and Mg ions with a 5 x 10(5) cfu/mL inocula. MIC of 16 ug/mL or less for amikacin was found in 39% of the isolates; MIC 50 was 32 ug/mL and MIC 90 greater than 64 ug/mL. Ciprofloxacin had MIC 50 of 1 ug/mL and an MIC 90 greater than 4 ug/mL. Higher MICs to ciprofloxacin were seen in Pseudomonas spp.
Download full-text PDF |
Source |
---|
ACS Med Chem Lett
December 2024
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China.
The widespread use of tylosin family drugs in clinical practice has led to bacterial resistance and reduced therapeutic efficacy. We designed and synthesized a series of new semisynthetic derivatives of tylosin with 5--mycaminosyltylonolide as the mother nucleus, mainly by introducing a variety of amino groups at its C-23 position. Some of the compounds showed high antibacterial activity against Gram-negative and Gram-positive bacteria.
View Article and Find Full Text PDFInt J Nanomedicine
November 2024
Translational and Clinical Research Institute, Newcastle University Medical School, Newcastle Upon Tyne, NE2 4HH UK.
Introduction: Given the increasing frequency of drug-resistant bacteria and the limited progress in developing new antibiotics, it is necessary to explore new methods of combating microbial infections. Nanoparticles, particularly silver nanoparticles (Ag-NPs), have shown exceptional antibacterial characteristics; however, elevated concentrations of Ag-NPs can produce noticeable levels of toxicity in mammalian cells.
Aim: This study examined the potential synergistic effect of combining a low dosage of Ag-NPs and anti-pseudomonas drugs against (ATCC strain) and eleven clinical isolates from cystic fibrosis patients.
Biofouling
October 2024
Department of Drug and Medicines, São Paulo State University (UNESP), School of Pharmaceutical Sciences, São Paulo State, Brazil.
is a multidrug-resistant yeast that has seen a worrying increase during the COVID-19 pandemic. Give7/n this, new therapeutic options, such as controlled-release nanomaterials, may be promising in combating the infection. Therefore, this study aimed to develop amphotericin B (AmB) and micafungin (MICA)-loaded nanoemulsions (NEMA) and evaluated against biofilms of .
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
July 2024
Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science &Technology, Normal University, Nanchang, 330013, China.
This research paper utilizes a fused-in-silico approach alongside bioactivity evaluation to identify active FtsZ inhibitors for drug discovery. Initially, ROC-guided machine learning was employed to obtain almost 13182 compounds from three libraries. After conducting virtual screening to assess the affinity of 2621 acquired compounds, cluster analysis and bonding model analysis led to the discovery of five hit compounds.
View Article and Find Full Text PDFNew Microbiol
July 2024
Bahrain Oncology Center, King Hamad University Hospital, Infectious Diseases Department, Muharraq, Bahrain.
Herein, we aimed to investigate the antifungal susceptibility pattern of Candida auris clinical strains in our setting Bahrain Oncology Center-King Hamad University Hospital-Bahrain. C. auris strains isolated from different clinical specimens in the Microbiology Laboratory from October-2021 to November-2022 were evaluated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!